Alaunos Therapeutics, Inc. (TCRT) intrinsic value & 10-year financials
Alaunos Therapeutics, Inc. (TCRT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 55.2% a year to $5.0K, with an average return on invested capital of -252.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.63
- Market cap
- $5.1M
- Revenue (FY2025)
- $5.0K
- Revenue growth (10-yr CAGR)
- -55.2%
- ROIC (10-yr avg)
- -252.3%
- Free cash flow (FY2025)
- -$3.0M
TCRT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $5.0K | -$4.2M | -$2.20 | -$3.0M | -84500.0% | -434.7% |
| FY2024 | $10.0K | -$4.7M | -$2.92 | -$5.0M | -48120.0% | -768.9% |
| FY2023 | $5.0K | -$35.1M | -$2.20 | -$30.3M | -685340.0% | -375.9% |
| FY2022 | $2.9M | -$37.7M | -$0.17 | -$29.4M | -1201.4% | -259.4% |
| FY2021 | $398.0K | -$78.8M | -$0.37 | -$64.8M | -19484.7% | -668.9% |
| FY2020 | $0 | -$80.0M | -$0.38 | -$66.8M | — | -537.6% |
| FY2019 | — | -$117.8M | -$0.70 | -$41.1M | — | -699.2% |
| FY2018 | $146.0K | -$53.1M | $0.96 | -$49.9M | -36921.9% | 945.0% |
| FY2017 | $6.4M | -$54.3M | -$0.53 | -$55.4M | -837.3% | 62.4% |
| FY2016 | $6.9M | -$165.3M | -$1.32 | -$58.9M | -2409.4% | 213.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Alaunos Therapeutics, Inc. is facing top-line stagnation, with revenue contracting over the decade.
Alaunos Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just 3.7% ROIC.
Over the decade, Alaunos Therapeutics, Inc. shows that management has aggressively returned capital to shareholders by retiring 98.5% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Alaunos Therapeutics, Inc. is modeled at -55.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-84.38 per share.